Immunotherapy for Pancreatic Cancers—Challenges and Perspectives
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (15 August 2023) | Viewed by 307
Special Issue Editors
Interests: pancreatic cancer; translational research; biomarkers
Special Issue Information
Dear Colleagues,
In this Special Edition of Cancers, we intend to challenge some preconceived ideas about immunotherapy in the treatment of pancreatic cancer. The first of these is that the relatively low level of neo-antigens in pancreatic cancers precludes adoption of this form of therapy. We will discuss alternative forms of treatment such as adoptive cell therapy (ACT) that do not rely on mutational heterogeneity. We will also invite discussion of alternative explanations for the lack of success in immunotherapy to date with cancers of the pancreas, including with high-grade neuroendocrine neoplasms, where the mutational load is relatively high. Leading on from this discussion, we will examine how combinations of therapy could improve response, including the use of agents to interfere with the expression of ARG1 and NOS2 enzymes in myeloid cells reprogramming the tumor microenvironment so it does not interfere with ACT. Finally, we will address the biomarkers that may allow targeted versions of immunotherapy for individual pancreatic cancer patients.
Prof. Dr. William Greenhalf
Prof. Dr. Daniel H. Palmer
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- adoptive cell therapy
- checkpoint inhibitors
- pancreatic ductal adenocarcinoma
- neuroendocrine
- biomarkers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
